AUD12.05
3.29% yesterday
Australia, Dec 30, 06:10 am CET
ISIN
AU000000CUV3
Symbol
CUV
Sector
Industry

Clinuvel Pharmaceutical Target price 2024 - Analyst rating & recommendation

Clinuvel Pharmaceutical Classifications & Recommendation:

Buy
100%

Clinuvel Pharmaceutical Price Target

Target Price AUD26.58
Price AUD12.05
Potential
Number of Estimates 2
2 Analysts have issued a price target Clinuvel Pharmaceutical 2025 . The average Clinuvel Pharmaceutical target price is AUD26.58. This is higher than the current stock price. The highest price target is
AUD30.16 150.29%
register free of charge
, the lowest is .
A rating was issued by 2 analysts: 2 Analysts recommend Clinuvel Pharmaceutical to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Clinuvel Pharmaceutical stock has an average upside potential 2025 of . Most analysts recommend the Clinuvel Pharmaceutical stock at Purchase.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Jun '24 2025
Estimates
Revenue Million AUD 88.18 98.20
12.59% 11.36%
EBITDA Margin 50.74% 46.95%
4.71% 7.46%

1 Analyst has issued a sales forecast Clinuvel Pharmaceutical 2025 . The average Clinuvel Pharmaceutical sales estimate is

AUD98.2m
Unlock
. This is
11.36% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
AUD98.2m 11.36%
Unlock
, the lowest is
AUD98.2m 11.36%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 AUD88.2m 12.59%
2025
AUD98.2m 11.36%
Unlock
2026
AUD102m 4.07%
Unlock
2027
AUD105m 3.13%
Unlock

1 Analyst has issued an EBITDA forecast Clinuvel Pharmaceutical 2025 . The average Clinuvel Pharmaceutical EBITDA estimate is

AUD46.1m
Unlock
. This is
3.16% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
AUD46.1m 3.16%
Unlock
, the lowest is
AUD46.1m 3.16%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 AUD44.7m 7.29%
2025
AUD46.1m 3.04%
Unlock
2026
AUD45.0m 2.39%
Unlock
2027
AUD47.8m 6.22%
Unlock

EBITDA Margin

2024 50.74% 4.71%
2025
46.95% 7.46%
Unlock
2026
44.03% 6.22%
Unlock
2027
45.35% 3.00%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Jun '24 2025
Estimates
EV/Sales 4.49

Based on analysts' sales estimates for 2025, the Clinuvel Pharmaceutical stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.00 39.61%
2025
4.49 10.23%
Unlock
2026
4.31 3.91%
Unlock
2027
4.18 3.04%
Unlock

P/S ratio

Current 7.07 31.10%
2025
6.35 10.20%
Unlock
2026
6.10 3.91%
Unlock
2027
5.92 3.04%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today